Venous thromboembolism in diabetic patients

Czech version

Authors: Lucia Stančiaková ¹; Miroslava Dobrotová ¹; Pavol Hollý ¹; Tomáš Bolek ²; Matej Samoš ²; Peter Galajda ²; Marián Mokáň ²; Peter Kubisz ¹; Ján Staško ¹
Authors‘ workplace: Národné centrum hemostázy a trombózy, KHaT JLF UK a UNM, Martin ¹; I. interná klinika JLF UK a UNM, Martin ²
Published in: Forum Diab 2021; 10(2): 98-102
Category:

Overview

Cardiovascular diseases are the leading cause of mortality in patients with diabetes mellitus (DM) type 2. DM is one of the risk factors of the development of venous thromboembolism (VTE). DM is well-known risk factor of ischemic heart disease associated with atherosclerosis, but its role in the etiopathogenesis of VTE has not been fully clarified. Many estimates from previous studies did not took into account potentially confounding effect of obesity. As the clinical manifestations and diagnostics of both clinical states are described elsewhere, in this article, we will focus predominantly on etiopathogenesis and prevention of this life-threatening complication of DM. Simultaneously, we add the chapter about VTE in DM and CoronaVirus Disease 19 (COVID-19).

Keywords:

diabetes mellitus – etiopathogenesis – Venous thromboembolism

Sources

1. Harding JL, Pavkov ME, Magliano DJ et al. Global trends in diabetes complications: a review of current evidence. Diabetologia 2019; 62(1): 3–16. Dostupné z DOI: <http://dx.doi.org/10.1007/s00125–018–4711–2>.

2. Aynalem SB, Zeleke AJ. Prevalence of Diabetes Mellitus and Its Risk Factors among Individuals Aged 15 Years and Above in Mizan- Aman Town, Southwest Ethiopia, 2016: A Cross Sectional Study. Int J Endocrinol. 2018; 2018: 9317987. Dostupné z DOI: <http://dx.doi.org/10.1155/2018/9317987>.

3. Kaur R, Kaur M, Singh J. Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: molecular insights and therapeutic strategies. Cardiovasc Diabetol 2018; 17(1): 121. Dostupné z DOI: <http://dx.doi.org/10.1186/s12933–018–0763–3>.

4. Data and Statistics on Venous Thromboembolism. In: Centers for Disease Control and Prevention. Dostupné z WWW: <https://www.cdc.gov/ncbddd/dvt/data.html>. [28–04–2021].

5. Heit JA, Leibson CL, Ashrani AA et al. Is Diabetes Mellitus an Independent Risk Factor for Venous Thromboembolism? A Population- Based Case-Control Study. Arterioscler Thromb Vasc Biol 2009; 29(9): 1399–1405. Dostupné z DOI: <http://dx.doi.org/10.1161/ATVBAHA.109.189290>.

6. Carr ME. Diabetes mellitus: a hypercoagulable state. J Diabetes Complications 2001; 15(1): 44–54. Dostupné z DOI: <http://dx.doi.org/10.1016/s1056–8727(00)00132-x>.

7. Lespagnol E, Dauchet L, Pawlak-Chaouch M et al. Early Endothelial Dysfunction in Type 1 Diabetes Is Accompanied by an Impairment of Vascular Smooth Muscle Function: A Meta-Analysis. Front Endocrinol (Lausanne) 2020; 11: 203. Dostupné z DOI: <http://dx.doi.org/10.3389/fendo.2020.00203>.

8. Peng YH, Lin YS, Chen CH et al. Type 1 diabetes is associated with an increased risk of venous thromboembolism: A retrospective population- based cohort study. PLoS One 2020; 15(1): e0226997. Dostupné z DOI: <http://dx.doi.org/10.1371/journal.pone.0226997>.

9. Leonard J, Caputo LM, Carrick MM et al. Does diabetes type increase the odds of venous thromboembolism following traumatic injury? Trauma Surg Acute Care Open 2016; 1(1): e000003. Dostupné z DOI: <http://dx.doi.org/10.1136/tsaco-2016–000003>.

10. Mi Y, Yan S, Lu Y et al. Venous thromboembolism has the same risk factors as atherosclerosis. A PRISMA-compliant systemic review and meta-analysis. Medicine (Baltimore) 2016; 95(32): e4495. Dostupné z DOI: <http://dx.doi.org/10.1097/MD.0000000000004495>.

11. Yang G, Meng F, Liu Y et al. Diabetes mellitus and risk of deep vein thrombosis after total knee replacement: a meta-analysis of cohort studies. Int J Clin Exp Med 2015; 8(6): 9086–9092.

12. Avogaro A, Albiero M, Menegazzo L et al. Endothelial Dysfunction in Diabetes. The role of reparatory mechanisms. Diabetes Care 2011; 34(Suppl 2): S285-S290. Dostupné z DOI: <http://dx.doi.org/10.2337/dc11-s239>.

13. Galajda P, Mokáň M. Poruchy hemostázy pri diabetes mellitus. Osveta: Martin 2001. ISBN-13: 978–80–88866–18–3. ISBN-10: 80– 88866–18–9.

14. Vinik AI, Erbas T, Park TS et al. Platelet Dysfunction in Type 2 Diabetes. Diabetes Care 2001; 24(8): 1476–1485. Dostupné z DOI: <https://doi.org/10.2337/diacare.24.8.1476>.

15. Scordi-Bello I, Kirsch D, Hammers J. Fatal Pulmonary Thromboembolism in Patients with Diabetic Ketoacidosis: A Seven-Case Series and Review of the Literature. Acad Forensic Pathol 2016; 6(2): 198–205. Dostupné z DOI: <http://dx.doi.org/10.23907/2016.022>.

16. Kearon C, Akl EA, Ornelas J et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest 2016; 149(2): 315–352. Dostupné z DOI: <http://dx.doi.org/10.1016/j.chest.2015.11.026>.

17. Pechlivani N, Ajjan RA. Thrombosis and Vascular Inflammation in Diabetes: Mechanisms and Potential Therapeutic Targets. Front Cardiovasc Med 2018; 5: 1. Dostupné z DOI: <http://dx.doi.org/10.3389/fcvm.2018.00001>.

18. Zhang YM, Jiang X, Sun YS. Effect of rivaroxaban on preventing deep vein thrombosis in aged diabetics with femoral neck fractures after hip replacement. Biosci Rep 2017; 37(3): BSR20170289. Dostupné z DOI: <http://dx.doi.org/10.1042/BSR20170289>.

19. Keenan CR, Murin S, White RH. High risk for venous thromboembolism in diabetics with hyperosmolar state: comparison with other acute medical illnesses. J Thromb Haemost 2007; 5(6): 1185–1190. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1538–7836.2007.02553.x>.

20. Lu DY, Huang CC, Huang PH et al. Metformin use in patients with type 2 diabetes mellitus is associated with reduced risk of deep vein thrombosis: a non-randomized, pair-matched cohort study. BMC Cardiovasc Disord 2014; 14:187. Dostupné z DOI: <http://dx.doi.org/10.1186/1471–2261–14–187>.

21. Managing Patients with Diabetes for Risk of Thrombosis. In: EndocrineWeb. Dostupné z WWW: <https://www.endocrineweb.com/professional/endocrinology/role-glucose-update-metabolism-blood-clotting-uncovered>. [28–04–2021].

22. Gerotziafas GT, Catalano M, Colgan MP et al. Guidance for the Management of Patients with Vascular Disease or Cardiovascular Risk Factors and COVID-19: Position Paper from VAS-European Independent Foundation in Angiology/Vascular Medicine. Thromb Haemost 2020; 120(12): 1597–1628. Dostupné z DOI: <http://dx.doi.org/10.1055/s-0040–1715798>.

23. Sardu C, Gambardella J, Morelli MB et al. Hypertension, Thrombosis, Kidney Failure, and Diabetes: Is COVID-19 an Endothelial Disease? A Comprehensive Evaluation of Clinical and Basic Evidence. J Clin Med 2020; 9(5): 1417. Dostupné z DOI: <http://dx.doi.org/10.3390/jcm9051417>.

24. Roy S, Mazumder T, Banik S. The Association of Cardiovascular Diseases and Diabetes Mellitus with COVID-19 (SARS-CoV-2) and Their Possible Mechanisms. SN Compr Clin Med 2020; 1–6. Dostupné z DOI: <http://dx.doi.org/10.1007/s42399–020–00376-z>.